[go: up one dir, main page]

MX2020011668A - Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales. - Google Patents

Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.

Info

Publication number
MX2020011668A
MX2020011668A MX2020011668A MX2020011668A MX2020011668A MX 2020011668 A MX2020011668 A MX 2020011668A MX 2020011668 A MX2020011668 A MX 2020011668A MX 2020011668 A MX2020011668 A MX 2020011668A MX 2020011668 A MX2020011668 A MX 2020011668A
Authority
MX
Mexico
Prior art keywords
sex
dual
treatment
receptor antagonists
hormone
Prior art date
Application number
MX2020011668A
Other languages
English (en)
Inventor
Mike Trower
Original Assignee
Kandy Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56008636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020011668(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kandy Therapeutics Ltd filed Critical Kandy Therapeutics Ltd
Publication of MX2020011668A publication Critical patent/MX2020011668A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Multicomponent Fibers (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta invención se refiere al nuevo uso de antagonistas duales de receptores NK-1/NK-3 o una sal farmacéuticamente aceptable de éstos en el tratamiento de enfermedades dependientes de hormonas sexuales.
MX2020011668A 2015-05-18 2017-10-03 Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales. MX2020011668A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562162870P 2015-05-18 2015-05-18

Publications (1)

Publication Number Publication Date
MX2020011668A true MX2020011668A (es) 2021-01-15

Family

ID=56008636

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012720A MX377052B (es) 2015-05-18 2016-05-16 Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
MX2020011668A MX2020011668A (es) 2015-05-18 2017-10-03 Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017012720A MX377052B (es) 2015-05-18 2016-05-16 Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.

Country Status (22)

Country Link
US (3) US10195205B2 (es)
EP (2) EP3574907B1 (es)
JP (1) JP6902682B2 (es)
KR (1) KR102704783B1 (es)
CN (4) CN114306335A (es)
AU (2) AU2016264034B2 (es)
BR (1) BR112017024852B1 (es)
CA (1) CA2984591A1 (es)
CY (1) CY1122180T1 (es)
DK (1) DK3297631T3 (es)
ES (1) ES2753539T3 (es)
HR (1) HRP20192132T1 (es)
HU (1) HUE047732T2 (es)
LT (1) LT3297631T (es)
MX (2) MX377052B (es)
PL (1) PL3297631T3 (es)
PT (1) PT3297631T (es)
RS (1) RS59608B1 (es)
RU (1) RU2743206C2 (es)
SI (1) SI3297631T1 (es)
SM (1) SMT201900719T1 (es)
WO (1) WO2016184829A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3384930A1 (en) 2013-03-15 2018-10-10 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding
WO2019175253A1 (en) * 2018-03-14 2019-09-19 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
AU2018419533A1 (en) * 2018-04-19 2020-11-12 Abbvie Inc. Methods of treating heavy menstrual bleeding
MX2022005867A (es) * 2019-11-15 2022-06-14 Kandy Therapeutics Ltd Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2 -metilfenil)piridin-3-amina, un intermediario clave de nt-814.
MX2023001199A (es) * 2020-07-30 2023-03-13 Acer Therapeutics Inc Antagonistas de receptor nk para pacientes con cancer.
CN116322544B (zh) 2020-08-12 2024-08-02 云杉生物科学公司 用于治疗多囊卵巢综合征的方法和组合物
WO2023147135A1 (en) * 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Nk receptor antagonists for treatment of prostate cancer
EP4431512A1 (en) * 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282721B6 (sk) * 1994-05-27 2002-11-06 Smithkline Beecham S.P.A. Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie
HU218910B (hu) * 1994-07-22 2000-12-28 Ortho Pharmaceutical Corporation Gonadotrofin-felszabadító hormon antagonista-polipeptidek alkalmazása emlősben ivarmirigy-szteroid-függő állapotok gyógykezelésére szolgáló gyógyszerkészítmények előállítására
GB9907571D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Compounds
CA2412355A1 (en) 2000-06-12 2001-12-20 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
ATE358482T1 (de) * 2002-07-03 2007-04-15 Schering Corp 1-amido-4-phenyl-4-benzyloxymethyl-piperidin derivative und verwandte verbindungen als neurokinin-1 (nk-1) antagonsisten zur behandlung von erbrechen, depressionen, angstzustände und husten
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
CA2509090C (en) 2002-12-23 2012-01-24 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
US7525659B2 (en) 2003-01-15 2009-04-28 Negevtech Ltd. System for detection of water defects
DE602004008631T2 (de) * 2003-07-03 2008-07-10 F. Hoffmann-La Roche Ag Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2525B1 (en) 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
CA2565953A1 (en) 2004-05-12 2005-11-24 Pfizer Products Inc. Piperidine derivatives as nk1 and nk3 antagonists
DE102004033902A1 (de) 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
WO2006013205A1 (en) 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030600A1 (en) 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
MY145713A (en) * 2005-09-09 2012-03-30 Smithkline Beecham Corp Hexahydropyrazino [2,1-c][1,4]oxazin-8(1h)-yl pyridine derivatives and their use in the treatment of psychotic disorders
AR056544A1 (es) * 2005-09-29 2007-10-10 Wyeth Corp Derivados fenilaminopropanol y metodos de uso de los mismos
AU2008232311A1 (en) * 2007-03-27 2008-10-02 Niall Corcoran Methods and compositions for treating prostate cancer
CN101657418B (zh) 2007-04-20 2012-05-30 弗·哈夫曼-拉罗切有限公司 作为nk1/nk3受体双重拮抗剂的吡咯烷衍生物
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
BR112012003435A2 (pt) * 2009-08-27 2016-02-23 Glaxosmithkline Llc formas anidras de um derivado de píridina
US8415884B2 (en) 2009-09-08 2013-04-09 Tokyo Electron Limited Stable surface wave plasma source
US8487102B2 (en) 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
KR20130115108A (ko) * 2010-05-28 2013-10-21 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 올리고－벤즈아미드 화합물 및 이의 용도
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
ES2376564B1 (es) 2010-08-12 2013-01-24 Manuel Vicente Salinas Martín Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
WO2014089019A1 (en) 2012-12-03 2014-06-12 University Of Washington Through Its Center For Commercialization Methods and compositions for treating vasomotor symptoms
GB201315846D0 (en) 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
WO2019175253A1 (en) * 2018-03-14 2019-09-19 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists

Also Published As

Publication number Publication date
CN114306347A (zh) 2022-04-12
RS59608B1 (sr) 2020-01-31
SI3297631T1 (sl) 2019-12-31
KR102704783B1 (ko) 2024-09-10
HUE047732T2 (hu) 2020-05-28
PL3297631T3 (pl) 2020-03-31
AU2020201074B2 (en) 2021-07-29
CY1122180T1 (el) 2020-11-25
SMT201900719T1 (it) 2020-01-14
EP3574907A1 (en) 2019-12-04
HRP20192132T1 (hr) 2020-02-21
JP2018515445A (ja) 2018-06-14
RU2743206C2 (ru) 2021-02-16
MX377052B (es) 2025-03-07
CN107635557A (zh) 2018-01-26
LT3297631T (lt) 2019-10-25
ES2753539T3 (es) 2020-04-13
CA2984591A1 (en) 2016-11-24
RU2017134908A3 (es) 2019-10-23
CN114306335A (zh) 2022-04-12
WO2016184829A1 (en) 2016-11-24
AU2016264034B2 (en) 2020-03-05
US20210128574A1 (en) 2021-05-06
BR112017024852A2 (pt) 2018-08-07
EP3574907B1 (en) 2023-08-23
PT3297631T (pt) 2019-10-10
US10195205B2 (en) 2019-02-05
EP3297631A1 (en) 2018-03-28
BR112017024852B1 (pt) 2023-10-31
KR20180004815A (ko) 2018-01-12
AU2016264034A1 (en) 2017-10-26
RU2017134908A (ru) 2019-06-18
MX2017012720A (es) 2018-02-09
JP6902682B2 (ja) 2021-07-14
EP3297631B1 (en) 2019-09-04
CN114272242A (zh) 2022-04-05
US20210236506A1 (en) 2021-08-05
US20160339037A1 (en) 2016-11-24
AU2020201074A1 (en) 2020-03-05
DK3297631T3 (da) 2019-11-11
EP3574907C0 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
MX2020011668A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB201709456D0 (en) Therapeutic agents
MY192927A (en) Fused bicyclic compounds for the treatment of disease
NZ730123A (en) Processes and intermediates in the preparation of c5ar antagonists
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
IL281089A (en) LINGO–1 antagonists and uses for the treatment of demyelinating disorders
IL249455A0 (en) Complexes of mineral-amino acids with active substances
IL269853A (en) Proteins for the treatment of epithelial barrier activity disorders
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
GB201603104D0 (en) Therapeutic agents
PH12018500282A1 (en) Cgrp receptor antagonists
SG10201908881PA (en) Fused bicyclic compounds for the treatment of disease
GB201700553D0 (en) Therapeutic agents
LT3119752T (lt) 3,4-diamino-6-chlorpirazin-2-karboksamido junginiai, skirti enac sąlygotų ligų gydymui
GB201600376D0 (en) Novel therapeutic agents
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
MA54630A (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitment des maladies neurodégénératives
PL3494122T3 (pl) Podstawione rybonukleozydy heteropentadienopirolopirymidynowe do użytku terapeutycznego
GB201620948D0 (en) Therapeutic agents
GB201616563D0 (en) Therapeutic agents
IL246817A0 (en) Strength testing for medical agents
GB201702052D0 (en) Therapeutic agents